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Background: The systemic use of corticosteroid is the treatment of choice for patients with 
pemphigus vulgaris (PV), but adverse effects are frequent. To date, the use of rituximab 
(RTX) for PV patients is usually indicated when they failed first line immunosuppressive 
therapies. The early use of RTX could  theoretically lessen adverse effects. 
Methods: We performed a single-center study on patients with predominantly oral PV, 
treated with systemic corticosteroid and the prompt use of 1000 mg of intravenous RTX two 
week apart. We evaluated the clinical response and the reported adverse effect during a 
period of 24 months, comparing those with a previously published series. 
Results: The study group comprised 11 patients, while the control group comprised 98 
patients. The average time to achieve complete clinical remission was 3.2±2.72 months. 
Study group took steroids for a mean time of 11.09± 2.02 months, and they are all actually 
disease free with no medication. Only 3 patients (27.3%) developed plain side effects. The 
effect of the length of the corticosteroid therapy on the side effects (also adjusted by sex, 
age, and clinical oral involvement) was statistically different in the two groups: the prompt 
use of RTX reduced of 94% the chance to have adverse effects (p=.001). 
Conclusions: This is the first report of the use of RTX as first line of therapy for PV patients 
with predominantly oral involvement. With the proposed regimen, the adverse effects have 
been minimized compared with classic systemic corticosteroid-centred therapy. Multi-center 
randomized controlled trail are however necessary.  
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1. INTRODUCTION 
Pemphigus is a group of potentially life-threatening and organ-specific autoimmune 
disorders, described with cutaneous and/or mucosal blistering. Pemphigus vulgaris (PV), 
usually  affects first the oral  mucosa and its management aims to induce and maintain 
clinical remission with as few as possible adverse effects. Because of the lack of 
international agreed recommendations, either the dosage of corticosteroids and choice of 
adjuvant agents usually reflect the experience of clinicians at various centers.1-3 Recently, 
we confirmed that systemic corticosteroid should be considered the mainstay medication for 
predominantly oral involvement.1  
Rituximab (RTX) is a chimeric monoclonal anti-CD20 antibody that targets pre-B cells and 
mature B cells, resulting in complement and antibody-dependent cytotoxicity, antibody-
dependent cell-mediated cytotoxicity, and apoptosis.4 RTX has been used as first line 
intervention together with short-term prednisone  in patients with mucosal-cutaneous PV 
and it was suggested to be more effective than prednisone alone, with fewer adverse 
events.5 Few data are on RTX effectiveness are  available for predominantly oral PV  and 
most of the studies report different regimens; moreover,  it has been not yet used as a first 
line intervention in oral cases.1, 6, 7 
We have evaluated the efficacy and safety of prompt use of RTX joint with prednisone in a 
cohort of Italian patients with predominantly oral PV. 
 
2. MATERIALS AND METHODS 
We describe a case series of newly diagnosed PV patient treated with steroid and with the 
immediate use of RTX since January 2017, with a follow up to 24 months. The diagnosis 
was confirmed by histopathological examination and direct immunofluorescence studies. 
The patient group received treatment with systemic corticosteroids (typical starting dose of 
1.5 mg/kg per day of prednisone, for variable lengths of time usually of 2-4 months, and then 
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tapered in other 8 months approximately), together with RTX (1 g IV, two infusions two week 
apart within 6 months from diagnosis) provided at the Center of Research of 
Immunopathology and Rare Diseases (S. Giovanni Bosco Hospital, Turin, Italy). We 
described therapeutic response and adverse effects as previously.1 
The ethics review board of the CIR - Dental School approved the study (CIR-PO 2018/2435). 
Qualitative variables were described via frequencies and percentages; quantitative ones via 
median and interquartile range (IQR), due to the low sample size in the new group and the 
following lack of the normality assumption. As control group, we decided to select all PV 
patients reported recently by our group and treated with systemic medication.1 Sixteen 
patients of this group received intravenous RTX, after standard treatment failure. 
Differences were tested via chi squared test or Fisher's exact test when appropriate for 
qualitative variables and via the non-parametric  Mann-Whitney U test for quantitative ones. 
Univariate and multivariate logistic regression models were computed.  Odds Ratios (OR) 
and their 95% Confidence Interval (95% CI) were reported. Statistical analyses were 
performed using R version 3.4.0. The level of significance was set at 0.05. 
 
3. RESULTS 
The study group comprised 11 unrelated Caucasian patients (7 female and 4 male), with a 
median age of 60.00 [49.00, 68.00].  
The control group comprised 95 unrelated Caucasian patients (60 female and 35 male), 
together with 2 female and 1 Afro-Caribbean male (F : M; 1.65 : 1), mean age 54.56 
(±14.95).1 
The oral mucosal disease severity (MDS) was assessed as moderate (buccal and 
gingivolabial mucosal involvement) in 2 patients, and severe (extensive oral mucosal 
involvement) in 9 patients. The average time to achieve complete clinical remission was 
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3.2±2.72 months after commencement of therapy, very similar to the control group (3.9 ± 
2.72 months) (Figure 1).  
 Patients in the test group took corticosteroids for a mean time of 11.09 month (± 2.02) and 
they are all actually disease free with no medication, compared to only 41% of the control 
group in remission and off medication. Only 3 patients (27.3%) developed 1 or 2 more of the 
following adverse effects:  one patient developed hypertension and hyperglycaemia; the 
second one  hypertension, folliculitis and the third fatigue, hypertension and hyperglycaemia. 
These effects, however, disappeared after 6 months from the withdrawal of corticosteroid 
therapy. Contrarily, in the control group, sixty-nine patients (72.63%) developed detectable 
adverse effects from the immunosuppressive drugs. 
Table 1 described the difference in adverse effects between the test and the control group. 
The effect of the length of the steroid therapy on the side effects (also adjusted by sex, age, 
and clinical oral involvement) was statistically different: the prompt use of RTX reduced of 
94% the chance to have adverse effects (p=.001). 
 
4. DISCUSSION 
To date, the gold standard of therapies for oral PV is generally thought to be a relatively 
long-course of corticosteroid therapy. Usually, prednisone is given at 0.5 mg to 1.5 
mg/Kg/day, combined with an immunosuppressive adjuvant drugs such as azathioprine or 
mycophenolate mofetil immediately at the start of therapy or during the tapering stage. 
However, the above-mentioned regimes may still cause many and potentially complex 
adverse effects, particularly complications due to expected prolonged use of prednisone (>4 
months) or corticosteroid dose dependency above minimal therapy (>10 mg/day).1, 4 
RTX is usually considered for PV as third-line treatment, in refractory disease or in case of 
contraindications to immunosuppressants.8 
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Recently, it has been reported that first-line use of TX plus short-term prednisone for patients 
with PV or pemphigus foliaceous could be more effective than prednisone alone, and could 
cause  fewer adverse events.4 Joly and co-workers used 2 infusions (1000 mg each, on day 
0 and day 14) with 2 additional half-dosage infusions at months 12 and 18.  
We are likely the first to report the use of RTX, together with systemic corticosteroids as first 
line intervention in patients with predominantly oral PV. 
Notably, we avoided in the current group of patients to deliver  additional RTX infusions 
because the results were excellent with just the first two infusions. Even more importantly, 
with the proposed regimen, the adverse effects have been significantly reduced.  
 Our experience suggests that RTX as first line therapy with prednisone can be as effective 
and possibly safer that traditional just corticosteroid centred therapies for predominantly oral 
PV. 
 However, further trials with larger cohorts and possibly randomized and controlled are 
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